Julius Namonyo Kalamya et al.

Cervical cancer services for women living with HIV, Uganda

This online first version has been peer-reviewed, accepted and edited, but not formatted and finalized with corrections from authors and proofreaders

Provision of cervical cancer services for women living with HIV, Uganda

Julius Namonyo Kalamya,a Jennifer DeCuir,b Sarah X Alger,a Josephine Ninsiima,c Joseph Kabanda,a Patrick Komakech,d Marvin Lubega,e Grace Nantege,a Estella Birabwa,f Tamara Nyombi,d Phoebe Namukanja,a Steven Baveewo,a Julius Ssendiwala,c Jacqueline Calnan,d Christina Mwangi,a Phoebe Namukanja,a Steven Baveewo,a Julius Ssendiwala,c Jacqueline Calnan,d Christina Mwangi,a Mina Nakawuka,g Gerald Mutungi,g Lisa J Nelsona & Emilio Dirlikov.a

a Division of Global HIV and TB, United States Centers for Disease Control and Prevention (CDC), United States Embassy Kampala, 1577 Ggaba Road, PO Box 7007, Kampala, Uganda.
b Epidemic Intelligence Service, CDC, Atlanta, Georgia, United States of America.
c Monitoring and Evaluation Technical Support, Kampala, Uganda.
d United States Agency for International Development, Kampala, Uganda.
e Clinton Health Access Initiative, Kampala, Uganda.
f United States Department of Defense, Kampala, Uganda.
g Ministry of Health, Kampala, Uganda.

Correspondence to Julius Namonyo Kalamya (email: hno4@cdc.gov).

(Submitted: 13 May 2023 – Revised version received: 23 January 2024 – Accepted: 19 February 2024 – Published online: 12 March 2024)

Abstract

Objective To describe the scale-up of cervical cancer screening and treatment for women living with human immunodeficiency virus (HIV) aged 25–49 years in Uganda, and to analyse the programme data.

Methods The health ministry targeted existing HIV clinics in a 2-year scale-up of cervical cancer screening services from October 2020. In preparation, we trained healthcare workers to assess women attending HIV clinics for screening eligibility, provided either by human papillomavirus (HPV) testing and/or visual inspection with acetic acid. Clinic staff treated women with precancerous cervical lesions with thermocoagulation or referred women with suspected cancer to external services. We analysed data reported every 6 months for the number of clinics offering screening, screening uptake, the number of positive diagnoses and the number of women who received treatment.

Findings The number of HIV clinics offering cervical cancer screening services increased from 11 before the programme launch to 1571. During the programme, screening uptake increased from 5.0% (6506/130 293) to 107.3% (151 872/141 527) of targets. The cumulative proportion of positive diagnoses was 5.9% (23 970/407 323) overall, but was much lower for diagnoses in clinics offering visual inspection only.
compared with clinics offering HPV testing. Although the proportion of women receiving treatment if positive increased from 12.8% (53/413) to 84.3% (8087/9592), the World Health Organization target of 90% was not reached.

**Conclusion** We demonstrated marked increases, potentially replicable by other countries, in screening and treatment. These increases could be improved further by expanding HPV testing and same-day treatment of precancerous lesions.

**Introduction**

Cervical cancer is a disease of the female reproductive tract caused primarily by oncogenic types of human papillomavirus (HPV). In 2020, it was the fourth most common cancer among women worldwide, with an estimated 604,000 new cases and 342,000 deaths. Low- and middle-income countries are disproportionately affected, with the highest levels of incidence and mortality occurring in sub-Saharan African countries. Women living with human immunodeficiency virus (HIV) are six times more likely to develop invasive cervical cancer compared with women without HIV infection. In 2021, the World Health Organization (WHO) released updated clinical guidelines for cervical cancer, recommending that women living with HIV aged 25–49 years are screened every 3–5 years.

In Uganda, cervical cancer is the most common malignancy among women and the leading cause of cancer-related death. In 2010 the health ministry published a strategic plan for cervical cancer control, recommending annual screening for women living with HIV. However, a decade later less than 1% (11/1797) of HIV clinics supported by the United States President’s Emergency Plan for AIDS Relief (PEPFAR) providing antiretroviral therapy (ART) to women aged 25–49 years had introduced cervical cancer services. Among the HIV clinics that had introduced such services, uptake was low mainly because of a lack of resources for commodities and equipment due to competing health-care priorities. By 2018, more than 80% of about 6000 women referred each year for cervical cancer treatment to the Uganda Cancer Institute presented with either stage 3 or stage 4 cancer, of whom 70–80% were HIV positive. In 2020, estimated HIV prevalence among women aged 15 years and older was 6.8%, and there were an estimated 810,000 women living with HIV. During that year, approximately 6959 Ugandan women were diagnosed with cervical cancer and 4607 women died of the disease.

Given the high cervical cancer burden, low screening uptake and large population of women living with HIV, in October 2020 the health ministry launched an intensive scale-up of cervical cancer services among women living with HIV aged 25–49 years. In alignment with the
WHO global strategy for cervical cancer elimination, the health ministry adopted a screen-and-treat approach to identify and treat precancerous cervical lesions in a timely manner. The key goals of this scale-up were to: improve patient literacy; build health workers’ capacity to provide high-quality cervical cancer services, especially the capacity of midwives and nurses to deliver screening and treatment of precancerous lesions; increase the availability and accessibility of high-quality cervical cancer services for women living with HIV; provide timely referrals to specialist care for suspected cervical cancer; and contribute to eliminating cervical cancer by 2030 through the 90:70:90 strategy (in which 90% of girls are fully vaccinated with HPV vaccine by age 15 years, 70% of women are screened with a high-performance test by age 35 years and again by age 45 years, and 90% of women identified with cervical disease receive treatment).

We describe the nation-wide scale-up of cervical cancer screening and treatment in terms of its development and implementation. We also analyse the programme data for the 2-year period from its launch date, including the number of HIV clinics offering cervical cancer screening services, the number of women living with HIV screened, the number of women screened positive and the number of women receiving treatment.

Methods

Development

Under the leadership of the Ministry of Health AIDS Control Program, the development of our scale-up of cervical cancer services for women living with HIV was supported by multiple internal and external stakeholders. We established a national coordination committee, bringing together experts from a wide range of relevant departments (e.g. noncommunicable diseases and reproductive health), local institutions (e.g. Uganda Cancer Institute and PEPFAR implementing partners) and international stakeholders (e.g. WHO Country Office in Uganda; PEPFAR; the Global Fund to Fight AIDS, Tuberculosis and Malaria; and the Clinton Health Access Initiative). We obtained the largest proportion of the required financial resources from PEPFAR, with additional support provided by the Global Fund and the Clinton Health Access Initiative.

Our phased approach to the scale-up included: (i) materials preparation (March–August 2020), which included a review of cervical cancer strategy and guidelines, the development of tools and standard operating procedures, and the finalization of procurement plans, including
commodity quantifications; (ii) training and delivery of commodities (September–December 2020), which included training required staff down to regional and district levels (starting with a national training-of-trainers), and HIV clinic preparations (including delivery of initial screening commodities and treatment equipment); (iii) HIV clinic-level activities (October 2020–March 2021), including training clinic staff and starting the screening and treatment services; and (iv) catching up from the effects of the coronavirus disease (COVID-19) pandemic (April–September 2021). During the final catch-up phase, some clinics were updated to improve the space available for screening and treatment, and implementation was fast-tracked, resulting in a large increase in access to screening and treatment.

Implementation

We trained health-care workers to assess women living with HIV attending clinics for ART and other HIV services for screening eligibility at triage, and provide health education on cervical cancer. Screening is now offered as part of the routine service delivery, requiring informed consent from eligible women. Those who consent to be screened either (i) undergo visual inspection with acetic acid or (ii) are tested for HPV followed by a visual inspection with acetic acid if positive. For the second method, a health-care provider instructs women on collecting a vaginal sample; samples are then tested using GeneXpert® (Cepheid, Sunnyvale, United States of America), following manufacturer instructions and health ministry guidelines. HIV clinics without GeneXpert® machines, or clinics with GeneXpert® machines but capacity limitations (e.g. lack of HPV cartridges, or competing testing needs with tuberculosis and COVID-19), offer screening by visual inspection with acetic acid only. Clinic staff schedule women who screen negative by either method for rescreening in 3 years.

We also trained health-care staff to use the results of visual inspection with acetic acid to determine the appropriate treatment for women who screen positive. Those for whom eligible precancerous cervical lesions have been identified are treated with ablation (primarily thermocoagulation, with cryotherapy used at a few sites), ideally on the same day as screening. Women with lesions covering more than 75% of the cervix are ineligible for ablation, and are instead referred to regional hospitals for a loop electrosurgical excision procedure. Clinic staff schedule women who have undergone either type of treatment for rescreening after 1 year to assess for lesion recurrence and potential treatment needs. Women with lesions potentially
indicative of cervical cancer are referred to regional hospitals for biopsy and evaluation by gynaecologists. Hospital health-care workers refer women diagnosed with cervical cancer to the Uganda Cancer Institute or satellite sites for further management.

**Targets**
Of the 1797 PEPFAR-supported HIV clinics serving women aged 25–49 years, we targeted a total of 1789 (99.6%) for the provision or enhancement of cervical cancer services during years 1 and 2. The health ministry targeted 302 HIV clinics per 6-month period in year 1 (including the original 11), increasing to 592 then 593 for the two 6-month periods in year 2. To ensure that the most at-risk and age-eligible women benefitted from the scale-up, the health ministry set 6-month screening targets of 130,293 women living with HIV (annual total of 260,586 women) for year 1 and 141,527 women living with HIV (annual total of 283,054 women) for year 2. We estimated that the proportion screening positive for cervical cancer from HPV test and/or visual inspection with acetic acid would be 5–25%. In alignment with the WHO global strategy for the elimination of cervical cancer, the health ministry programme aims to treat 90% or more of women diagnosed with cervical disease.

**Data analysis**
We analysed data archived in the PEPFAR Monitoring, Evaluation, and Reporting Database for the 2-year scale-up. These data are routinely collected as part of HIV care and treatment services, and are reported every 6 months by PEPFAR-supported HIV clinics providing cervical cancer services.

To quantify the scale-up of cervical cancer services at HIV clinics, we calculated the number of PEPFAR-supported HIV clinics serving eligible women living with HIV, determined as those that reported any data on cervical cancer screening during each 6-month period, as a proportion of the number of HIV clinics targeted for scale-up.

We calculated the number of women living with HIV who were screened as a proportion of the target screening number for each 6-month period. We calculated the number of women living with HIV who screened positive by either HPV and/or visual inspection with acetic acid as a proportion of the total number of women living with HIV who were screened for each 6-month period, and compared this proportion with the expected proportion of women screening positive.
Because screening method was not reported in the database we assumed that: (i) women screening positive at HIV clinics without GeneXpert® machines received visual inspection only, and (ii) women screening positive at HIV clinics with GeneXpert® machines may have received HPV testing followed by visual inspection or, because of capacity limitations on HPV testing in some clinics, visual inspection only.

We calculated the number of women living with HIV who received treatment for precancerous cervical cancer lesions as a proportion of the number who screened positive for each 6-month period, and compared this proportion with the WHO treatment target of 90% or more.8

Results

Service provision
We observed that the number of HIV clinics serving eligible women living with HIV reporting cervical cancer screening increased from 11 before the health ministry scale-up to 1571 HIV clinics (87.8% of the cumulative 2-year scale-up target of 1789 HIV clinics) in September 2022 (Table 1). These 1571 HIV clinics providing cervical cancer services represent 87.4% (1571/1797) of all PEPFAR-supported HIV clinics serving eligible women. Of these 1571 HIV clinics, 5.3% (83) had GeneXpert® machines with which to provide HPV testing and 94.7% (1488) provided screening via visual inspection with acetic acid only.

Screening
Of the 1 215 789 people living with HIV receiving PEPFAR-supported HIV treatment on 30 September 2020, 44.8% (545 188) were women living with HIV aged 25–49 years, who were considered eligible for cervical cancer services. Only 5.0% (6 506/130 293) of the first 6-month screening target was achieved (Fig. 1; Table 1). However, screening uptake increased by the fourth 6-month period to 107.3% (151 872/141 527) of the target for that period. Overall, 407 323 women living with HIV were screened during the 2-year period, comprising 74.9% (407 323/543 640) of the cumulative target and 74.7% (407 323/545 188) of eligible women living with HIV.

Positive diagnoses
During the 2-year period, 5.9% (23,970/407,323) of screened women living with HIV screened positive by either HPV testing and/or visual inspection with acetic acid; the number of positive diagnoses as a proportion of number screened was greater than 5% during each of the 6-month periods. HIV clinics without GeneXpert® machines, that is, clinics offering screening by visual inspection only, reported positive diagnoses of 3.6% (10,827/298,345) of women screened. However, HIV clinics with GeneXpert® machines, assumed to indicate screening by HPV testing followed by visual inspection or potentially visual inspection only, reported positive diagnoses of 12.1% (13,143/108,978) of women screened.

**Treatment**

During the 2-year period, 72.7% (17,416/23,970) of women living with HIV who screened positive received treatment. The proportion of women receiving treatment increased over time from 12.8% (53/413) during October 2020–March 2021 to 84.3% (8,087/9,592) during April–September 2022 (Fig. 1; Table 1).

**Discussion**

Our scale-up allowed the successful integration of cervical cancer services into HIV clinics across Uganda, providing services to three quarters of all estimated eligible women living with HIV. We observed the number of women living with HIV who were screened and treated per 6-month period to increase by a factor of 23 (from 6506 to 151,872) and 153 (from 53 to 8,087), respectively, during the 2-year period. The overall number of women diagnosed positive as a proportion of the number of women screened remained above the expected 5% threshold.

Despite the successes of our programme, limitations and challenges remain. First, despite continual PEPFAR data quality assurance activities, data quality can be affected by reporting challenges (e.g. site-level electricity or internet outages preventing data transmission). Another potential bias in the data is that, given potential patient and provider treatment delays, it is quite possible that women could have been treated in a different 6-month period from that in which they screened positive, leading to artificially lower treatment rates.

Second, we observed a negative impact of the COVID-19 pandemic on service delivery. Because of reduced access to clinics by women and a disruption in the supply of commodities, only 5% of the first 6-month screening target was achieved.
Third, the proportion of women screening positive at HIV clinics that only offer visual inspection with acetic acid is less than 5%. Visual inspection is subjective, that is, vulnerable to lower sensitivity depending on the experience of health-care providers\textsuperscript{12} with possible unrecognized precancerous lesions. To improve the quality of screening and limit the risk of false-negative results, experienced midwives have been providing support, supervision and additional training since October 2022. Expanded HPV testing capacity is also being planned.

Fourth, among women screening positive, the proportion of those receiving treatment remained below the WHO benchmark of 90%. This statistic could be improved by expanding the volume of same-day treatment of precancerous lesions. Same-day treatment was limited at the programme start by supply chain disruptions caused by the COVID-19 pandemic affecting the delivery of thermocoagulators. Despite COVID-19, all HIV clinics had the appropriate equipment by September 2021, and the proportion of women receiving treatment improved from this date. Another barrier to same-day treatment was reporting delays in HPV test results; such delays meant that women may have left the clinic before results become available, preventing same-day treatment and increasing loss to follow-up. To address these gaps, all women living with HIV who have screened positive according to either HPV testing and/or visual inspection with acetic acid are tracked to ensure they receive treatment.

To conclude, we have demonstrated the importance of planning and coordination with different stakeholders to strengthen the health-care system, including cervical cancer education for patients and capacity-building for health workers. The scale-up programme achieved marked increases in the number of women screened and, in those who screened positive, the number of women treated. These advances are expected to reduce morbidity and mortality due to cervical cancer among women living with HIV in Uganda. We anticipate that our experience of developing and implementing a national health-care programme aligned with WHO global benchmarks can be useful to other countries.

**Funding:**
This project was supported by PEPFAR through the United States Centers for Disease Control and Prevention (award no. 0900f3eb81a9093b).

**Competing interests:**
None declared.
References


Table 1. **Cervical cancer screening indicators among women living with HIV aged 25–49 years, Uganda, October 2020–September 2022**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeted clinics offering cervical cancer services</td>
<td>91/302 (30.1)</td>
<td>470/302 (155.6)</td>
<td>807/592 (136.3%)</td>
<td>203/593 (34.2%)</td>
<td>1 571/1 789 (87.8)</td>
</tr>
<tr>
<td>Screening uptake</td>
<td>6 506/130 293 (5.0)</td>
<td>102 912/130 293 (79.0)</td>
<td>146 033/141 527 (103.2)</td>
<td>151 872/141 527 (107.3)</td>
<td>407 323/543 640 (74.9)</td>
</tr>
<tr>
<td>Positive diagnoses</td>
<td>413/6 506 (6.3)</td>
<td>6 342/102 912 (6.2)</td>
<td>7 623/146 033 (5.2)</td>
<td>9 592/151 872 (6.3)</td>
<td>23 970/407 323 (5.9)</td>
</tr>
<tr>
<td>Positive diagnoses at clinics offering visual inspection with acetic acid only</td>
<td>60/3 266 (1.8)</td>
<td>2 495/74 688 (3.3)</td>
<td>4 279/109 433 (3.9)</td>
<td>3 993/110 958 (3.6)</td>
<td>10 827/298 345 (3.6)</td>
</tr>
<tr>
<td>Positive diagnoses at clinics offering HPV testing</td>
<td>353/3 240 (10.9)</td>
<td>3 847/28 224 (13.6)</td>
<td>3 344/36 600 (9.1)</td>
<td>5 599/40 914 (13.7)</td>
<td>13 143/108 978 (12.1)</td>
</tr>
<tr>
<td>Women receiving treatment if positive</td>
<td>53/413 (12.8)</td>
<td>3 581/6 342 (56.5)</td>
<td>5 695/7 623 (74.7)</td>
<td>8 087/9 592 (84.3)</td>
<td>17 416/23 970 (72.7)</td>
</tr>
</tbody>
</table>

HIV: human immunodeficiency virus; HPV: human papilloma virus.
Fig. 1. Cervical cancer screening indicators among women living with HIV aged 25–49 years, Uganda, October 2020–September 2022

HIV: human immunodeficiency virus.